The single study provided does not actually investigate Boswellia or its effects on brain health — it examines ARTIVeda, an artemisinin-based supplement derived from Artemisia, as a treatment for mild-to-moderate COVID-19. As a result, no research synthesis on Boswellia and brain health can be drawn from the linked evidence. Readers interested in the science behind Boswellia for neurological or cognitive outcomes should consult literature specifically investigating Boswellia serrata or its active compounds, such as boswellic acids, in relevant study populations.
Citations from PubMed and preprint sources. Match score (0-100) reflects automated search ranking, not clinical appraisal.
| Title | Type | Year | Direction | Match |
|---|---|---|---|---|
| Targeting TGF-β pathway with COVID-19 Drug Candidate ARTIVeda/PulmoHeal Accel... | Other | 2021 | Neutral | 67 |